Search Results 2271-2280 of 14798 for anti-TNF drugs

1. Testosterone (Topical Application Route) Proper Use - Mayo Clinic

   This medicine comes with a Medication Guide and patient instructions. Read and follow these instructions carefully. Ask your doctor if you have any questions.

2. Scorpion (Centruroides) Immune F(Ab)2 (Intravenous Route) Proper Use - Mayo Clinic

   Proper Use. Drug information provided by: Merative, Micromedex®. A nurse or other trained health professional will give you this medicine in a hospital.

3. (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer - Mayo Clinic

   The purpose of this study is to identify a (Z)-endoxifen dose that achieves (Z)-endoxifen steady-state plasma concentrations (Css) between 500-1000 ng/mL.

4. A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma - Mayo Clinic

   Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs ...

5. Pulmonary Medicine - Overview - Mayo Clinic

   This tradition of collaboration helps ensure your doctor develops an individualized treatment plan that considers your needs and all aspects of your condition.

6. A Study of Lenvatinib for Treating Patients with Metastatic or Advanced Pheochromocytoma or Paraganglioma that Cannot be Removed by Surgery - Mayo Clinic

   ... treatment for their cancer; NOTE: adjuvant anti-estrogen/hormonal therapy for breast cancer is allowed. Participating Mayo Clinic locations. Study statuses ...

7. Sunscreen Agent (Topical Application Route) Description and Brand Names - Mayo Clinic

   Chemical sunscreen agents protect you from the sun by absorbing the ultraviolet (UV) and visible sun rays, while physical sunscreen agents reflect, scatter, ...

8. Crizotinib (Oral Route) Proper Use - Mayo Clinic

   This medicine comes with a Medication Guide. Read and follow these instructions carefully. Ask your doctor or pharmacist if you have any questions. Swallow the ...

9. A Study to Evaluate Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations - Mayo Clinic

   Treatment with any systemic anti-cancer therapy, radiation therapy, or experimental agent within ≤ 3 weeks of first dose of study treatment or are ...

10. Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Subject is receiving other ongoing anti-myeloma therapy. Subject has received any of the following within 7 days prior to the first dose of study drug:.